JP2019525924A - がんを処置するための併用療法 - Google Patents

がんを処置するための併用療法 Download PDF

Info

Publication number
JP2019525924A
JP2019525924A JP2019503517A JP2019503517A JP2019525924A JP 2019525924 A JP2019525924 A JP 2019525924A JP 2019503517 A JP2019503517 A JP 2019503517A JP 2019503517 A JP2019503517 A JP 2019503517A JP 2019525924 A JP2019525924 A JP 2019525924A
Authority
JP
Japan
Prior art keywords
compound
formula
chemotherapeutic agent
leukemia
inv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019503517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525924A5 (enExample
Inventor
エイチ． ブッシュウェラー、ジョン
エイチ． ブッシュウェラー、ジョン
イレンデュラ、アヌラダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation filed Critical University of Virginia Patent Foundation
Publication of JP2019525924A publication Critical patent/JP2019525924A/ja
Publication of JP2019525924A5 publication Critical patent/JP2019525924A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2019503517A 2016-07-27 2017-07-27 がんを処置するための併用療法 Pending JP2019525924A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367263P 2016-07-27 2016-07-27
US62/367,263 2016-07-27
PCT/US2017/044124 WO2018022855A1 (en) 2016-07-27 2017-07-27 Combination therapies for treating cancer

Publications (2)

Publication Number Publication Date
JP2019525924A true JP2019525924A (ja) 2019-09-12
JP2019525924A5 JP2019525924A5 (enExample) 2020-07-30

Family

ID=61016782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503517A Pending JP2019525924A (ja) 2016-07-27 2017-07-27 がんを処置するための併用療法

Country Status (13)

Country Link
US (1) US11241421B2 (enExample)
EP (1) EP3490557B1 (enExample)
JP (1) JP2019525924A (enExample)
KR (1) KR20190032370A (enExample)
CN (1) CN109475542A (enExample)
AU (1) AU2017302330A1 (enExample)
BR (1) BR112019000049A2 (enExample)
CA (1) CA3028461A1 (enExample)
EA (1) EA201990395A1 (enExample)
IL (1) IL263942A (enExample)
MX (1) MX2019000179A (enExample)
WO (1) WO2018022855A1 (enExample)
ZA (1) ZA201900438B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019274588A1 (en) 2018-05-24 2020-11-26 Lucio Hernan CASTILLA Combination therapies for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501707A (ja) * 2005-07-06 2009-01-22 カニサ・ファーマシューティカルズ・インコーポレイテッド 癌の処置のためのゾスキダル、ダウノルビシン、およびシタラビン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
US8106033B2 (en) 2005-03-11 2012-01-31 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
WO2010132684A2 (en) * 2009-05-13 2010-11-18 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501707A (ja) * 2005-07-06 2009-01-22 カニサ・ファーマシューティカルズ・インコーポレイテッド 癌の処置のためのゾスキダル、ダウノルビシン、およびシタラビン

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 124, no. 21, JPN6021019905, 2014, pages 390, ISSN: 0004664437 *
BLOOD, vol. 127, no. 1, JPN6021019907, 7 January 2016 (2016-01-07), pages 53 - 61, ISSN: 0004664438 *
BRITSH JOURNAL OF HAEMATOLOGY, vol. 93, JPN6021019910, pages 888 - 897, ISSN: 0004664440 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 34, JPN6021019908, 2007, pages 5442 - 5447, ISSN: 0004664439 *
SCIENCE, vol. 347, no. 6223, JPN6021019904, 13 February 2015 (2015-02-13), pages 779 - 784, ISSN: 0004664436 *

Also Published As

Publication number Publication date
AU2017302330A1 (en) 2019-01-17
EP3490557A1 (en) 2019-06-05
WO2018022855A1 (en) 2018-02-01
IL263942A (en) 2019-02-28
EP3490557A4 (en) 2020-04-01
KR20190032370A (ko) 2019-03-27
US11241421B2 (en) 2022-02-08
CN109475542A (zh) 2019-03-15
EP3490557B1 (en) 2022-09-07
ZA201900438B (en) 2019-10-30
CA3028461A1 (en) 2018-02-01
BR112019000049A2 (pt) 2019-04-02
EA201990395A1 (ru) 2019-07-31
US20190343820A1 (en) 2019-11-14
MX2019000179A (es) 2019-06-20

Similar Documents

Publication Publication Date Title
Ibrahim et al. Iron chelators in cancer therapy
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
US9963452B2 (en) Methods, compounds, and compositions for inhibition of ROS
US12208141B2 (en) Anti-cancer nuclear hormone receptor-targeting compounds
JP5973684B2 (ja) 癌治療のための使用
AU2018314236B2 (en) RNA aptamers against transferrin receptor (TfR)
US10702494B2 (en) Method for cancer treatment
CN118804914A (zh) 一种四环类化合物及其用途
KR102320885B1 (ko) 글루타민 수송체 억제제를 유효성분으로 포함하는 면역관문 억제제의 항암 효과 증진용 약학적 조성물
KR101930859B1 (ko) 피라지노-트리아진 유도체를 포함하는 비소세포성폐암 예방 및 치료용 조성물
JP2019525924A (ja) がんを処置するための併用療法
WO2019018785A2 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
CA3113408A1 (en) Cancer combination therapy using quinoline carboxamide derivative
HK40003583A (en) Combination therapies for treating cancer
WO2017210559A1 (en) Compounds and methods for treating fibrosis or cancer
JP2019014685A (ja) 抗がん剤
BR112020024037A2 (pt) compostos orgânicos
CN120815187A (zh) Hdac6抑制剂与btk抑制剂的药物组合及其用途
CN109952104A (zh) 二硫etp衍生物
CN121152622A (zh) 治疗癌症的方法
CN120860228A (zh) 新的药物组合及其用途
WO2025138294A1 (zh) hnRNPA2B1激动剂及其与免疫检查点抑制剂联用的肿瘤防治应用
KR20250105460A (ko) Kras 억제제 및 shp2 억제제를 포함하는 조합 요법
JPWO2010032436A1 (ja) ４−［［３，５−ビス（トリメチルシリル）ベンゾイル］アミノ］安息香酸を含有する抗腫瘍剤
CN120607482A (zh) 7-甲氧基-5,6-双甲基吖啶酮类化合物及其作为sting协同激动剂的医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211216